Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $13.1 Million

Posted by on Jun 21, 2015 in Newsroom | 0 comments

KNOXVILLE, TN. – Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (“Provectus” or the “Company”), a clinical-stage oncology and dermatology biopharmaceutical company, today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock with a public offering price of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock. The warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years...

Read More

vTv Therapeutics Files Registration Statement for Proposed Initial Public Offering

Posted by on Jun 16, 2015 in Newsroom | 0 comments

HIGH POINT, N.C. – Tv Thevrapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its Class A common stock. Piper Jaffray & Co. and Stifel are acting as joint book running managers for the offering. Canaccord Genuity and Janney Montgomery Scott will act as co-managers. The number of shares to be offered and...

Read More

Celtaxsys wraps up $45M funding round

Posted by on Jun 9, 2015 in Newsroom | 0 comments

ATLANTA, GA. – Celtaxsys Inc., a clinical stage drug development company based in Atlanta, completed a $45 million funding round, the company announced June 8. The $40 million Series D financing was led by Domain Partners VIII with additional funding from Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund. The Cystic Fibrosis Foundation Therapeutics, the nonprofit drug discovery and development arm of the Cystic Fibrosis Foundation, also provided a $5 million grant. Celtaxsys, which is focused on developing novel therapies for...

Read More

Parion inks deal that could exceed $1 billion

Posted by on Jun 8, 2015 in Newsroom | 0 comments

DURHAM, N.C. – Drug developer Parion Sciences reached a licensing deal for a possible cystic fibrosis treatment with Boston-based Vertex Pharmaceuticals (Nasdaq: VRTX) that will bring the Durham company $80 million up front and could bring more than $1 billion in a best-case scenario. In the deal, Vertex obtains worldwide development and commercial rights to Parion’s lead experimental drugs that could someday be used to treat CF and other pulmonary diseases. If the drugs show efficacy in trials and are ultimately approved by the U.S. Food and Drug Administration, Parion would receive...

Read More

Nuovo Biologics, LLC Announces Academic-Biotech Collaboration with Auburn University’s Research Initiative in Cancer

Posted by on Jun 4, 2015 in Newsroom | 0 comments

DAVIE, FL. – Researchers from South Florida based Nuovo Biologics LLC and Auburn University’s Research Initiative in Cancer (AURIC), have announced an exciting partnership to develop new therapies for cancer. Initially targeting canine malignant melanoma, or skin cancer, a deadly tumor that affects many dogs, the team will be testing Nuovo’s innovative anti-cancer peptide drug MMX™ for its ability to treat these tumors. The National Institutes for Health recently awarded a grant funded by the U.S. Food and Drug Administration to support a clinical trial of the new peptide...

Read More

Leica Microsystems buys Duke medical imaging spinout Bioptigen

Posted by on Jun 2, 2015 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – A buyout announcement on June 1, 2015, from Morrisville, N.C.-based medical imaging company Bioptigen is the latest evidence that support from the North Carolina Biotechnology Center can be important. The 2004 Duke University spinout, which makes specialized high-resolution imaging devices for non-invasive diagnoses of eye diseases and other medical applications, has reached agreement to be purchased by German powerhouse Leica Microsystems. Leica Microsystems, based in Wetzlar, Germany, a global leader in microscopy and imaging systems, said it’s buying...

Read More